Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy.

Autor: De Silva MK; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Chan DLH, Bernard EJ, Conner AJ; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Mascall SL; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Bailey DL, Roach PJ, Clarke SJ, Diakos CI, Pavlakis N, Schembri G

Publikováno v: Pancreas [Pancreas] 2024 Aug 01; Vol. 53 (7), pp. e560-e565.